Plain-English translation of NCT06695845 on ClinicalTrials.gov β Β· Source last updated Β· Translation generated Β· How we translate trials
Read our Breast Cancer research guide βPhase 2 β Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a new medication called for people with advanced cancers that have too much of a protein called HER2 on their tumor cells. The medication is designed to target and attack these HER2-positive cancer cells. Researchers want to see if this treatment can help people whose cancers have already progressed despite previous treatments.
Many advanced cancers with HER2 overexpression eventually stop responding to existing treatments, leaving patients with limited options. This trial is exploring whether this new medication could offer hope to people in that situation by attacking the cancer in a different way.
You likely qualify ifβ¦
You likely don't qualify ifβ¦
If you join this study, you would receive as an intravenous infusion (through a vein) at regular intervals as part of your cancer treatment. You would attend visits at the research center for the medication administration, blood tests, and imaging scans to see how your cancer is responding. The study will monitor you closely for any side effects and to measure whether the treatment is helping your cancer.
AI-generated summary from trial data Β· Jul 18, 2026 Β· Not medical advice
United States